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1. Introduction 
1.1 Adjuvant 
In the mid 1950s, we started to have a much better understanding of the biological 
mechanisms of establishment of metastases and the role of regional lymph nodes as an 
effective barrier to tumor spread, because malignant cells have been observed in the 
bloodstream (Fisher, Turnbull, 1955).  
Early studies with adjuvant chemotherapy after surgery in solid tumors (breast 
adenocarcinoma implanted in mice) began in 1957 (Shapiro, Fugman, 1957). Based on these 
findings, Bernard Fisher and colleagues began in 1958, the first collaborative study with the 
objective of evaluating the response to systemic administration of perioperative 
chemotherapy in patients with operable breast cancer (Fisher et al, 1958). Good results were 
obtained in relation to disease-free interval and overall survival in premenopausal women 
(Fisher et al, 1968). Similar results were also observed by other authors, with the use of 
multidrug therapy (cyclophosphamide, methotrexate and fluorouracil (CMF) with or 
without prednisone) in advanced breast cancer (BC)(Canellos et al, 1974 and 1976, 
Bonadonna et al, 1976). Therefore, the addition of adjuvant polychemotherapy in BC 
showed gain by controlling survival of micrometastases in patients with lymph nodes 
affected by cancer or not (Fisher et al, 1975; Bonadonna et al, 1976; Early Breast Cancer 
Trialists Collaborative Group (EBCTCG ), 1988; Bonadonna, Valagussa, 1983,1985,1987, 
Henderson, 1987, Fisher et al, 1989; Bonadonna et al, 1995; Mansour et al, 1998, Carlson et al, 
2000 and NIH 2000). 
1.2 Neoadjuvant therapy 
Neoadjuvant chemotherapy is defined as a treatment option where chemotherapy is 
introduced before local treatment, either surgery or radiotherapy (Bear, 1998). This was 
introduced by De Lena et al (1978) who administered adriablastin and vincristine in 110 
women with advanced BC, achieving response rates of 70% partial. 
The biological rationale for using neoadjuvant chemotherapy was based on observations in 
animal models where the removal of primary tumor growth accelerated due to changes in 
metastatic tumor kinetics, suggesting that growth factors derived from tumor influence the 
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development of micrometastases. The prior addition of chemotherapy such as 
cyclophosphamide in mice transplanted with murine mammary tumor cells showed a 
significant reduction in the proliferation rate of residual tumor and metastases, and 
prolonged their survival (Gunduz et al, 1979, Fisher et al, 1989b; Fisher et al, 1989c).  
The use of neoadjuvant chemotherapy has additional advantages in patients with locally 
advanced carcinoma, enhancing the possibility of performing conservative surgery due to 
the reduction of tumor size, as well as providing evidence in vivo of sensitivity to therapy 
and providing early treatment of micrometastases (Bonadonna et al. 1990; Wolff, Davidson, 
2000, Kafka et al 2003, Hutcheon, Heys, 2004).  
Studies demonstrated a significant increase in survival in patients with stage III breast 
carcinoma, influenced by neoadjuvant chemotherapy associated with local therapy 
(Canellos, 1976; Jacquillat et al, 1987 Valagussa et al, 1990). Six randomized trials 
compared the use of adjuvant and neoadjuvant therapy with the aim of measuring the 
survival of patients with complete clinical response rates from 6.6 to 41% and pathological 
complete rates of 3 to 29%, with high rates of breast conservation in patients undergoing 
neoadjuvant chemotherapy (Mauriac et al, 1991; Semiglazov et al, 1994; Scholl, 1994; 
Powles et al, 1995, van der Hage et al, 2001; Wolmark et al, 2001). One of the major studies 
related to neoadjuvant chemotherapy was the National Surgical Adjuvant Breast and 
Bowel Project B18 (NSABP B18), which showed no significant difference between the rates 
of disease-free survival and survival free of distant disease (among those who 
received neoadjuvant chemotherapy and those who received postoperative adjuvant 
chemotherapy). However, neoadjuvant chemotherapy allowed higher rates of 
conservative surgery and the study in vivo of tumor biology (Fisher et al, 1998). Further 
analysis, with a follow up of nine years, showed that patients under 49 years experienced 
a significant advantage in terms of survival rates and disease-free survival when they 
were submitted to primary chemotherapy in relation to patients 50 years or more, 
suggesting that age could influence the indication of neoadjuvant chemotherapy, 
continuing the strong correlation between the clinical primary tumor response to 
chemotherapy and prognosis (Wolmark et al, 2001).  
The neoadjuvant therapy was extended for the treatment of patients with operable breast 
tumors initially with different chemotherapy regimens and variable rates of clinical 
response (Scholl et al, 1994; Ragaz et al, 1997, Fisher et al, 1997, Fisher et al, 1998). The 
clinical response to neoadjuvant administration of chemotherapy, namely the reduction of 
tumor size, was 10 to 75% in several studies (Kafka et al, 2003).  
1.3 Mechanisms of resistance to chemotherapeutic agents 
The main reasons responsible for treatment failure in cancer patients are the mechanisms of 
drug resistance and emergence of disseminated disease (Terek et al, 2003). We identified 
two types of resistance most relevant to BC: primary resistance, which corresponds to the 
clinical situation where the patient showed no response to therapy, and secondary or 
acquired resistance in which, initially, there is an observed response and a subsequent 
failure of the treatment regimen (Kroger et al, 1999).  
Several mechanisms may cause the phenotype of multidrug resistance to chemotherapy 
drugs and are well characterized in in vitro experiments, including alterations in systemic 
pharmacology (pharmacokinetics and metabolism), extracellular mechanisms (tumor 
environment, multicellular drug resistance), and cellular mechanisms (cellular 
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pharmacology, activation and inactivation of drugs, modification of specific targets and 
regulatory pathways of apoptosis) (Leonessa et al, 2003, Riddick et al, 2005). Identification of 
factors that affect cell metabolism, which are related to drug resistance, will enable the 
identification of which patients are at particular risk of treatment failure.  
Among the biochemical and molecular mechanisms of drug resistance, we stress: changes in 
the activity of topoisomerase II, alterations in the DNA repair mechanism, overexpression of 
P-glycoprotein; high intracellular concentrations of enzymes purification of cellular 
metabolism - among them enzymes the family of glutathione S-transferases (GSTs) and 
changes in the mechanisms of signaling via c-Jun N-terminal kinase 1 (JNK1) -and 
"apoptosis signal-regulating kinase (ASK1) required for activation of the" mitogen-
activated protein (MAP kinases) in apoptosis and cellular restoration. These pathways are 
also mediated by proteins encoded by genes of GSTs (O'Brien, Tew, 1996; Burg, Mulder, 
2002, L'Ecuyer et al, 2004).  
Different response rates to particular chemotherapy regimens, as observed in patient groups 
with the same biological characteristics and stage, suggest the existence of different 
mechanisms of drug resistance, probably induced by genetic alterations (Hayes, Pulford, 
1995; O'Brien , Tew, 1996; Pakunlu et al, 2003).  
Among the mechanisms of purification of cellular metabolism involved in the inactivation 
of toxic substances to the cell there is the action of the enzyme family of GSTs in phase II 
metabolism of cell purification. The first evidence of their involvement in resistance to drugs 
used in chemotherapy have emerged from research published by scientific groups 
Schisswelbauer et al (1990), Tew (1994) and Hayes, Pulford, (1995). However, the 
relationship between GSTs and resistance to chemotherapy remains inconsistent (Riddick et 
al, 2005). This mechanism of resistance is related to the ability to regulate the action of 
enzymes involved in catalyzing electrophilic compounds harmful to cells from activation by 
cytochrome P-450 1A1 and 1B1 (Phase I). These compounds in turn are substrates for phase 
II enzyme systems, represented here by the family of GSTs, which are involved on two 
fronts in the process of drug resistance: production of protective enzymes of metabolism 
and cellular apoptotic processes via inhibition of JNK1 and ASK1 (Townsed, Cowan, 1989, 
Hamada et al, 1994; Tew, 1994; O'Brien, Tew, 1996; Gaudiano et al, 2000, O'Brien et al, 2000; 
Tashiro et al, 2001; Harbottle et al, 2001; Townsend, Tew, 2003b). 
1.3.1 Glutathione S-transferases (GSTs) 
The family of GSTs consists of eight classes termed cytosolic and symbolized by the Greek 
alphabet: Alpha, Kappa, Mu, Omega, Pi, Sigma, Theta and Zeta. They are highly 
polymorphic, with about 30% homology between their base sequences. Each of these classes 
has several alleles that reach 50% similarity between their base sequences, and are able to 
produce enzymes of phase II cell purification.  
Cellular purification occurs through the ability to regulate the action of protein kinases 
involved in the catalysis of electrophilic compounds harmful to cells (xenobiotics) from the 
activation by cytochrome P-450 1A1 and 1B1, such as genotoxic chemical carcinogens and 
cytotoxic agents chemotherapeutic drugs and their metabolites by means of connection to 
glutathione (Fig. 1) (Townsed, Cowan, 1989, Shea et al, 1990; Tew, 1994, Shimada et al, 1996; 
Townsend, Tew, 2003a, b; Daly, 2003). The enzymes of the GST family represents about 5 to 
10% of all cellular proteins (Burg, Mulder, 2002). 
Studies have shown that the GST enzyme complex participates in the JNK1 and ASK1 
pathways necessary for activation of MAP kinase signaling processes involved in apoptosis 
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and cellular restoration. They also participate in and catalyze the conjugation of electrophilic 
compounds and free radicals to the tri-peptide glutathione (γ-glu-cys-gly, or GSH), 
produced by GSH-reductase. Thus, they become less chemically reactive and more soluble, 
and its excretion facilitated by membrane enzyme complexes, among which stands out the 
GP1 enzyme encoded by the MRP1 gene family of ABC transporters (Arrick, Nathan, 1984; 
Townsed Cowan, 1989, Hamada et al, 1994; Tew, 1994; O'Brien, Tew, 1996, Morrow et al, 
1998, Gaudiano et al, 2000; Harbottle et al, 2001; Burg, Mulder, 2002; Townsend, Tew, 2003a, 
b; Parl, 2005).  
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Fig. 1. Conjugation of glutathione to a generic xenobiotic (X) via catalysis by GSTs to form a 
conjugate of GST. 
Glutathione (GSH) is a major intracellular non-protein substance present in the process of 
activation and inactivation of toxic substrates to the cell cycle. These reactions begins in the 
presence of free radicals and products released by the oxide-reactive phenomena of stress 
and inflammation than healthy and tumor cells are subjected (Arrick, Nathan, 1984; Russo, 
Mitchell, 1985, Asakura et al, 1999, Adler et al, 1999; Burg, Mulder, 2002; McIlwain et al, 
2006). Thus, GSH plays an important role in cell survival and can be found in high 
concentrations in tumor tissue, where the highest enzyme activity of GSTs family exists 
(O'Brien, Tew, 1996, O'Brien et al, 2000).  
GSH may present itself in several ways, most commonly its reduced sulfhydryl which is 
related to reactions with substances or reduced-oxide reactions with electrophilic 
substances. These reactions may be reversible or irreversible, spontaneous or mediated by 
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the enzymes of the family of GSTs (Arrick, Nathan, 1984; O'Brien, Tew, 1996; Burg, 
Mulder, 2002).  
GSH has four functions in the anti-cancer therapy: cell protection by blockade of toxic 
substances to the cell, mediating the formation of toxic to cells, cellular targeting, allowing the 
efflux and influx of substances through association with enzyme systems membrane and 
therapeutic interaction through changes in the effectiveness of certain drugs (Arrick, Nathan, 
1984). Among the substrates for the cytosolic enzymes of the family of GSTs are anti-neoplastic 
drugs such as melphalan, chlorambucil, adriamycin, cyclophosphamide, and platinum salts 
among others (Table 1), which, in the presence of these enzymes, have a lower intracellular 
concentration (Dirven, 1994; Paumi et al, 2001; Townsend, Tew, 2003a, b).  
 
Direct substrates of GSTs 
Chlorambucil  
Melphalan  
Nitrogen mustard  
Mustard Phosphoramide  
Acrolein  
Carmustine  
Hidroxialquilantes  
Ethacrynic acid  
Steroids  
Substances not characterized as direct substrates of GSTs 
Antimetabolites *  
Antitubulin drugs *  
Inhibitors of topoisomerases I and II *  
Bleomycin  
Hepsulfan  
Mitomycin C * 
Adriamycin *  
Cisplatin * 
Carboplatin  
* Requires activation of JNK for cytotoxicity 
(Adapted from Townsend, Tew, 2003b) 
Table 1. Nonsteroidal anti-neoplastic agents associated with increased levels of GST and 
cellular resistance. 
Cytotoxic and carcinogenic substances from the environment such as tobacco, alcohol 
and red meat, which are possibly related tocarcinogenesis in various organs such 
as breast, bladder and colon are also substrates for the enzymes of the GST family of 
1.3.1.1 The glutathione S-transferases (GSTs) and breast cancer 
The classes of GSTs are related to the BC classes Alpha, Theta, and Pi Mu. In this review we 
approach the last three, as they are most frequently studied and their analysis has provided 
further information in relation to adjuvant chemotherapy and CM.  
The proteins that belong to the Mu class are encoded by a group of genes located on 
chromosome 1 (GSTM 1-5). These genes are related to various diseases and susceptibility to 
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various forms of cancer (Townsend, Tew, 2003a). The GSTM1 gene (Genbank access number 
AY532926) is the most studied and has four different allelic forms (GSTM 1 * A, B 1 * 1 * 1 * 0 
null and Ax2 that are related to a variety of malignancies, as lung, colorectal, oropharyngeal, 
bladder and breast cancers (Bell et al, 1993; Ambrosone et al, 1995; Saarikoski et al, 1998; 
Helzlsouer et al, 1998; Jourenkova-Mironova et al, 1999, Dunning et al, 1999; Ambrosone et 
al, 2001; Loktionov et al, 2001 and Sgambati et al, 2002; Townsend, Tew, 2003a). However, 
some authors failed to demonstrate such a relationship (Bailey et al, 1998; Lizard-Nacolia et 
al , 1999; Garcia-Close et al, 1999).  
The enzymes encoded by the gene GSTM1 catalyze the conjugation of electrophilic 
compounds and free radicals by GSH and still exert an inhibitory effect on apoptosis via 
ASK1, independent of its catalytic action. This inhibition occurs while the enzyme 
complexes of GSTM1/ASK1 are related. In the presence of high concentrations of oxide-
reactive substances, this complex dissociates, releasing enzymes to ASK1 phosphorylation 
and signaling of apoptosis (Fig. 2) (Cho et al, 2001).  
The GSTM1 null genotype polymorphism results from the absence of the two alleles that 
determine gene expression. Thus, individuals with this genotype do not have the capacity to 
produce the enzymes necessary to catalyze the conjugation with GSH. Moreover, they also 
do not synthesize the proteins that coalesce to the ASK1 pathway proteins necessary for the 
inhibition of this pathway of apoptosis (Cho et al, 2001; McIlwain et al, 2006). The null 
genotype is present in 40 to 50% of the population (Tew, 1994), ranging from 22% in Nigeria, 
58% among Chinese, 45% in Western Europe and up to 67% in Australia, and it is related to 
better response to some classes of chemotherapeutic agents against various types of cancer 
(Alpert et al, 1997; Ambrosone et al, 2001; Sgambati et al, 2002; Autrup et al, 2002; 
Townsend, Tew, 2003a; Khedhaier et al, 2003; Parl , 2005).  
The proteins of the class Theta are encoded by two genes (T1 and T2), which are located 
on chromosome 22. The class GSTT1 (accession number AB057594 in Genbank) has three 
allelic forms: * The T1, T1 and T1 * B * 0 or null, but the latter is present between 10 and 
30% in African populations, 10% in European and American populations, and 64% in 
Asian populations (Townsend, Tew, 2003a). The T1 null allele is associated with a 
predisposition to some cancers (Townsend, Tew, 2003a; Saarikoski, 1998; Helzlsouer et al, 
1998; Jourenkova-Mironova et al, 1999 and Ambrosone et al, 2001), among them breast 
cancer in postmenopausal women, users of large quantities of alcoholic and longtime 
smokers, as well as in premenopausal women or nulliparous women who gave birth after 
age 30 (Park et al, 2000, Zheng et al, 2002, Zheng et al, 2003; Park et al, 2003), although 
some studies have not shown this relationship (Bailey et al, 1998; Garcia-Close et al, 1999; 
Millikan et al, 2000). The presence of the GSTT1 null form, in which there is not 
production of the enzymes, was associated with a better response to chemotherapy in 
patients with BC and the greater toxicity of some chemotherapeutic agents (Howells et al, 
2001;Naoe et al, 2002; Khedhaier et al, 2003).  
The class Pi, in turn, consists of only one protein encoded by a gene located on chromosome 11 
and called GSTP1 (GenBank access number AY324387). The GSTP1 gene has three allelic 
forms. The wild GSTP1 * A (Ile105Ile/Ala113Ala) genotype results in the replacement of Ile 
by Val at least one amino acid at codon 105 and) and two polymorphic forms, GSTP1 * B 
(Val 105Ile Val/113 Val) where, in addition to the alteration observed in GSTP1B * there is 
also replacement of Ala by Val in at least one amino acid codon 113. GSTP1 * C (105 Ile 
Ala. These forms are represented, respectively, in 68%, 26% and 7% of the Caucasian 
population (Townsend, Tew, 2003a).  
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The enzymes produced by gene GSTP1 * A prevails as a marker of carcinogenesis, since they 
are present in many tumor cells (Townsend, Tew, 2003a). Their relationship with cell 
protection is more related to performance in the apoptotic process. While the proteins 
encoded by the form "wild" GSTP1 * A are related to proteins of the JNK pathway, which 
inhibits apoptosis. This action will cease as the intensity of the phenomena of stress to which 
the cell is subjected to increase (fig 2), a phenomenon that occurs independently of its 
catalytic action. Since the polymorphic forms do not have the capacity to synthesize proteins 
that coalesce to JNK pathway enzymes and therefore do not have the ability to inhibit this 
pathway of apoptosis (Adler et al, 1999, Dang et al, 2005).  
 
Substancias 
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Drogas anti-neoplásicas
GSTM1
ASK1
GSTP1
JNK C-Jun
GSTP1
JNK C-Jun
Apoptose
ASK1GSTM1
P
P
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ASK1: "Apoptosis Signal-Regulating Kinase"  
JNK / Cjun: "c-Jun N-terminal Kinase 1"  
P: phosphorus atom 
Fig. 2. Action of GSTM1 and GSTP1 on pathways of apoptosis. While related enzymes ASK1 
and JNK1, the proteins encoded by the genes GSTM1 and GSTP1 exert an inhibitory effect of 
the corresponding pathways of apoptosis. Once exposed to substances oxide - reactive is the 
dissociation of the complex and phosphorylation of enzymes ASK1 and JNK1 pathways that 
pass the signal to the apoptosis pathway.  
The involvement of enzymes encoded by the gene GSTP1 * A in cell survival processes by 
catalyzing GSH seems to be a secondary response or consequence of the phenomena of 
stress to which the cells are submitted and occur in two ways of acting. The first one is 
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mainly related to anthracycline chemotherapy drugs and their substrates when associated 
with the ABC membrane transporters, responsible for one of the mechanisms of complex 
cellular efflux of GSH / drug. The second route of action would be on inhibitory complexes 
GSH / drugs on the enzymes of class GSTP1 * A, stimulating the process of apoptosis 
(Nakagawa et al, 1988.1990; Tew, 1994; Helzlsouer et al, 1998, Adler et al , 1999, Sweeney et 
al, 2000; Tashiro et al, 2001, Wang et al, 2001; Autrup et al, 2002; Townsend, Tew, 2003a, 
Huang et al, 2003; McIlwain et al, 2006).  
The presence and distribution of genes encoding the synthesis of enzymes of the family of 
GSTs in humans are variable. Some individuals do not express the genes GSTM1 and 
GSTT1, which determine the production of the enzyme purification. It is said that these 
people have "deleted" these alleles, known as GSTs null. These in turn are unable to promote 
catalysis of toxic substances with GSH and unable to promote inhibition of protein kinases 
required for the apoptotic process. Since the class Pi presents a substitution of amino acid 
isoleucine (Ile) by valine (Val) at codon 105 (GSTP1 * A → GSTP1 * B) This change, either in 
a strand of DNA (heterozygous) or both strands (homozygous) also makes cells unable to 
produce their own enzymes catalyzing GSH, which was similar to the GSTs null, and no 
longer inhibit the JNK apoptosis 1 (McIlwain et al, 2006).  
Comparable studies have shown varying results on the correlation between GSTs and 
chemotherapy response in various fields of oncology, including CM. Some authors have 
found a positive relationship between the presence of these enzymes and increased 
chemotherapeutic resistance (Hamada et al, 1994; Dirven et al, 1994, Morrow et al, 1998, 
Sweeney et al, 2000, O'Brien et al, 2000; Harbottle et al, 2001; Allan et al, 2001; Ambrosone et 
al, 2001; Naoe et al, 2002, Dasgupta et al, 2003, Huang et al, 2003, Yang et al, 2005), while 
others failed to demonstrate such a relationship (Moscow et al, 1989; Leyland-Jones et al, 
1991, Peters et al, 1993, Morrow et al, 1998, Alpert et al, 1997, Konishi et al, 1998; Osmak et 
al, 1998; Allan et al, 2001;Yang et al, 2005).  
1.3.2 P-glycoprotein  
The phenomenon of multi-drug resistance was first described in 1970 in ovarian cancer cells 
derived from Chinese hamsters exposed to increasing concentrations of various 
chemotherapeutic agents like actinomycin D, anthracyclines, vinca alkaloids and etoposide, 
until chemo resistant clones emerged (Bield, Riehm, 1970). Subsequently, Riordan and Ling 
(1979) showed the phenotype of multidrug resistance by measuring a deficit accumulation of 
cytotoxic drugs in the intracellular environment due to the action of a specific glycoprotein.  
One of the proteins responsible for determining this resistance phenotype is the P-
glycoprotein (Pgp), first described by Juliano and Ling (1976), responsible for the 
permeation and elimination of substances through the cell membrane (Carlsen et al, 1976; 
Riordan, Ling, 1979). This transmembrane protein has a molecular weight of 170 kd, 1280 
amino acids, is encoded by the gene MDR-1 and depends on energy coming from the 
metabolism of adenosine triphosphate (ATP) (Sauna et al, 2001). The MDR -1 gene in 
humans is located on the long arm of chromosome 7 (7 q 21) consisting of a central promoter 
region and 29 exons ranging from 6.3 to 210 kilobases (Bodor et al, 2005).  
Pgp is the most investigated of a superfamily called ATP - binding cassette transporters, or 
ABC multidrug transporters. It is encoded by some genes as MRP-1, MRP- 2, MRP-3, MRP-
4, MRP- 5,MRP-6, MRP-8, BSPE, BCRP (Goldstein, 1996; Scotto, 2003) ABC transporters are 
characterized functionally by their ability to eliminate antiblastic hydrophilic drugs from the 
intracellular environment , as shown below (Fig.3), (Sauna et al, 2001).  
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Fig. 3. Schematic representation of several proteins belonging to the superfamily multidrug 
ABC transporters, including Pgp. (Adapted from Sauna et al, 2001).  
Several drugs are substrates to the protein encoded by MRP’s as anthracyclines agents, 
vinca’s alkaloid, taxanes, actinomycin D, among others (Goldstein, 1996). It consists of a 
basic structure composed of two transmembrane domains (TMD) associated with two 
helical domains attached to nucleotides, in a conical shape of 10 nm depth, oriented 
perpendicular to the cell membrane, as visualized in Fig. 4 (Leonessa, Clarke, 2003).  
The three-dimensional shape of Pgp consists of a conical shape with a central pore, with its 
base open to the extracellular medium and its apex toward the intracellular region, virtually 
closed when this protein is not active (Leonessa, Clarke, 2003). The substrates of Pgp diffuse 
into the inner layers of the cell membrane along the propeller of their domains. With 
binding of the substrate on Pgp, ATP hydrolysis occurs after the conformational 
rearrangement of the protein obliterates the internal pore. Simultaneously, there is rotation 
of the helix, contributing to the decrease in the affinity between substrate and protein, 
eliminating it from the external environment. (Leonessa, Clarke, 2003). The mechanism by 
which Pgp interacts with this wide variety of substrates is still unclear. However, all 
substrates have in common that they are hydrophobic, have a molecular weight from 300 to 
2000 Da; and some carry a positive charge at neutral pH (Sauna et al, 2001).  
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Fig. 4. Schematic representation of Tansmembranas domains (TMD) that make up the 
various ABC multidrug transporters, including Pgp. (Adapted from Leonessa, Clarke, 2003)  
The expression of Pgp is not uniform across tissues, occurring both in normal and neoplastic 
tissues (Goldstein, 1996; Sauna et al, 2001) and is expressed physiologically in the blood-
brain barrier, liver, kidneys, intestine, adrenal glands and testicles, functioning to control the 
absorption, distribution and excretion of xenobiotics (Gottesmann, Pastan, 1993; Ambudkar 
et al, 1999). High levels of Pgp are found in renal tumors, liver and colon, low 
concentrations are identified in bladder tumors, breast cancer and stomach cancer. In 
tumors that have failed initial treatment, its expression is particularly high, as in breast, 
ovarian and non-Hodgkin lymphoma (Goldstein, 1996). Tumors that initially show 
resistance to drug infusion (primary resistance) to anthracycline derivatives also express 
high concentrations of P-glycoprotein (Goldstein, 1996).  
Pgp expression is and adverse prognostic factor on multivariate analysis, in patients with 
neuroblastoma and childhood sarcomas (Chan et al, 1990, Chan et al 1991), although this has 
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not been consistent association (Goldstein, 1996). The expression of Pgp associated with bcl-
2 in acute lymphoblastic leukemia in adults is an independent prognostic factor for disease-
free survival (Del Principe et al, 2003). In endometrial carcinoma, the immunohistochemical 
overexpression of Pgp is seen especially in premenopausal patients compared to patients of 
advanced age (Terek et al, 2003). In ovarian cancer, overexpression of MDR-1 gene is 
associated with decreased disease-free survival and tumor progression during 
chemotherapy (Kavallaris et al, 1996; Raspollini et al, 2005). In breast carcinoma, the 
expression of Pgp shows great heterogeneity due to the detection methods and different 
degrees of their induction by the use of multiple chemotherapeutic agents (Trock et al, 1997; 
Leonessa, Clarke, 2003). The expression of Pgp may be quantified by immunohistochemical 
analysis (IHC) or by use of polymerase chain reaction reverse transverse (RT-PCR) to 
identify the levels of ribonucleic acid type (mRNA) in order to identify its protein 
expression (Ro et al, 1990; Leonessa, Clarke, 2003). In patients with previously untreated 
breast carcinoma, the detection rates observed by IHC ranged from 0% (Yang et al, 1999) to 
100% (Del Vecchio et al, 1997) with average rates of 45.9% (Leonessa, Clarke, 2003). We 
verified the expression of Pgp mRNA by RT-PCR ranging from 0 to 100% with average rates 
of 63% (Leonessa, Clarke, 2003). The comparison between the methods of evaluation shows 
sensitivity of detection comparable between the two methods, with agreement rates of about 
73% between IHC and RT-PCR (Chevillard et al, 1996; Filipits et al, 1996).  
1.3.2.1 Polymorphism C3435T of the MDR-1 gene 
The single nucleotide polymorphism (SNP) is a substitution of bases, with sporadic 
occurrence in the population, which may or may not alter the function of the protein 
encoded by this codon (Hoffmeyer et al, 2000; Banhomme-Faivre et al, 2004). About 20 SNPs 
of the MDR-1 gene have been described by Hoffmeyer et al (2000) and Tanabe et al 
(2001). Brinkmann and Eichelbaum (2001) described 28 polymorphisms related to this gene, 
but the most studied polymorphism in these reports, with functional and clinical 
implications, is what happens C3435T in exon 26. In this SNP, the CC allele is considered as 
wild and replacing one or two of the nitrogen bases by T (CT or TT) represents the 
polymorphic genotype (Hoffmeyer et al 2000).  
Hoffmeyer et al (2000), assessed by RT-PCR the distribution of this polymorphism in 21 
healthy volunteers and showed that its occurrence was 23.9% homozygous and 
heterozygous, 48.3%. Cavaco et al (2003) reported that genotyping by using polymerase 
chain reaction linked to research the size polymorphism of restriction fragments (PCR-
RFLP) in a sample of 100 healthy Caucasian Portuguese, demonstrated frequencies of 64.5% 
for the 3435T SNP and 35.5% for the C3435 SNP, resulting in the incidence in this population 
of the following genotypes: CC 12%, CT 47% and 41% TT. Balram et al. in 2003 described the 
incidence of the SNP C3435T using the methodology of PCR-RFLP in an Asian population 
comprised of 290 individuals (98 Chinese, 99 Malays and 93 Indians) and found that the CC 
genotype was present in 24% of Chinese, 25% of Malays, and 18% of Indians; the CT 
genotype was found in 44% of Chinese, Malays 46%, and 39% of Indians; the TT genotype 
was found in 32% of Chinese, 28% of Malays, and 43% of Indians. Hamdy et al (2003), using 
PCR-RFLP, described the following allele frequency distribution in 200 individuals of 
Egyptian origin: 34% genotype CC, 51.50% CT and 14.50%.  
Experimental studies with cultured cell lines of breast and ovarian carcinomas subjected to 
the technique of RT-PCR showed that the basal expression of MDR-1 gene was absent or 
weakly present when associated with the TT genotype polymorphisms (Sauer et al, 
www.intechopen.com
 
Neoadjuvant Chemotherapy – Current Applications in Clinical Practice 
 
246 
2002 ). Hoffmeyer et al (2000) using the genotype represented by the SNP, determined the 
different forms of action of Pgp. These authors found, by sequencing the gene MDR-1 in 21 
healthy volunteers, there was a significant correlation between the C3435T polymorphism in 
exon 26 and the function of Pgp where individuals with the TT genotype had lower protein 
function as compared to normal CC heterozygotes; and CT showed intermediate levels of 
Pgp function. This differential protein function resulted in different phenotypes associated 
with serum concentrations of several known substrates of Pgp, such as oral digoxin, These 
authors found a significant inverse correlation between the polymorphism of exon 26 and 
plasma levels of digoxin, which reflects its activity in vivo. Individuals with the TT 
genotype in the intestinal epithelium had significantly higher blood levels of digoxin than 
individuals with the CC and CT genotype, demonstrating functional differences in their 
activity and in their expression (Hoffmeyer et al, 2000). Other authors such as Kim et al 
(2001), confirmed these findings through research of this functional polymorphism using the 
technique of single-strand conformation polymorphism (SSCP) in peripheral blood samples 
of different populations of Euro-American individuals and African Americans. These 
authors, using another Pgp substrate, fexofenadine, reported that CC homozygotes had 
higher rates of serum concentration of this substrate when compared with the TT genotype, 
also demonstrating functional differences between different polymorphisms of the MDR-1 
gene and consequently the expression of Pgp.  
This scenario has clear implications when considering the therapeutic use of drugs that are 
substrates related to Pgp and may, depending on the functional action determined by this 
polymorphism, have different rates of clinical response. Kafka et al. (2003), showed a 
significant correlation between the C3435T polymorphism of the MDR-1 gene and partial 
and complete response to primary chemotherapy with anthracyclines, in patients with 
locally advanced breast carcinoma. These authors found that the presence of genotype TT 
was significantly correlated with clinical response, suggesting that the demonstration of this 
polymorphism could identify tumors sensitive and resistant to anthracyclines, and allow 
better individualization of therapy.  
2. Summary 
Different response rates suggest the existence of different mechanisms of drug resistance. 
Identification of factors which are related to drug resistance will enable the identification of 
which patients are at particular risk of treatment failure. 
Pgp, encoded by the gene MDR-1, is the most investigated of a superfamily called ATP - 
binding cassette transporters, or ABC multidrug transporters. It has been involved as one of 
the drug-resistance’s mechanisms since 1976. On the other hand, the action of GSTs family 
as cellular enzymes purification as signaling apoptosis has been studied since 1990’s. The 
whole involvement of these enzymes is not totally clear yet, but seems that together 
represents a very important resistant mechanism to the chemotherapy treatments. 
More research is needed in this line of research to better understand these mechanisms. 
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